Personalis (NASDAQ:PSNL – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both healthcare companies, but which is the better investment? Get Personalis alerts:Analyst RecommendationsThis is a summary of current ratings for Personalis and Icon, as reported by MarketBeat. Given Icon’s stronger consensus rating and higher probable upside, analysts clearly believe Icon is more favorable than Personalis. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.